bluebird bio Is Priced Below IP Value
https://seekingalpha.com/article/4680031-bluebird-bio-is-priced-below-ip-value?source=feed_all_articles
Mar 22, 2024 - bluebird bio's stock plummeted by 64% on safety concerns and high pricing for sickle cell treatment. Read why its potential sale value remains higher than its market cap.
0
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
https://www.zacks.com/stock/news/2245547/opko-health-opk-and-entera-bio-announce-data-for-glp-2?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245547
Mar 25, 2024 - OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.
0
bluebird bio falls as accounting errors force restatements
https://seekingalpha.com/news/4083728-bluebird-bio-stock-falls-accounting-errors?source=feed_sector_healthcare
Mar 26, 2024 - bluebird bio (BLUE) faces a significant stock drop after revealing accounting errors that force it to restate financials for 2022 and 2023. Read more here.
0
Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline
https://www.zacks.com/stock/news/2246721/earnings-preview-bluebird-bio-blue-q4-earnings-expected-to-decline?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2246721
Mar 27, 2024 - Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock?
https://www.zacks.com/stock/news/2246863/kronos-bio-kron-upgraded-to-buy-what-does-it-mean-for-the-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2246863
Mar 27, 2024 - Kronos Bio (KRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
0
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
https://www.zacks.com/stock/news/2246798/why-is-theravance-bio-tbph-down-9-since-last-earnings-report?cid=CS-ZC-FT-realtime_blog-2246798
Mar 27, 2024 - Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
0
BIO-key International, Inc. (BKYI) Q4 2023 Earnings Call Transcript
https://seekingalpha.com/article/4681817-bio-key-international-inc-bkyi-q4-2023-earnings-call-transcript?source=feed_sector_transcripts
Apr 02, 2024 - BIO-key International, Inc. (NASDAQ:NASDAQ:BKYI) Q4 2023 Earnings Conference Call April 2, 2024 10:00 AM ETCompany ParticipantsBill Jones - IRMike...
0
Palisade Bio announces 1-for-15 reverse stock split
https://seekingalpha.com/news/4087067-palisade-bio-announces-1-for-15-reverse-stock-split?source=feed_sector_healthcare
Apr 03, 2024 - Palisade Bio announces 1-for-15 reverse stock split, effective April 5, to increase share price and comply with Nasdaq listing requirements.
0
Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?
https://www.zacks.com/stock/news/2250503/does-kala-bio-kala-have-the-potential-to-rally-152-83-as-wall-street-analysts-expect?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2250503
Apr 04, 2024 - The mean of analysts' price targets for KALA BIO (KALA) points to a 152.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
0
Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering
https://seekingalpha.com/article/4682514-gritstone-bio-granite-cancer-vaccine-data-overshadowed-by-offering?source=feed_all_articles
Apr 06, 2024 - Gritstone bio's GRANITE program shows promise in treating metastatic microsatellite stable colorectal cancer. Read why GRTS stock is a Buy.
0